Quest Diagnostics - Investment in der Pharma -Biotechbranche
eröffnet am 31.08.00 20:35:50 von
neuester Beitrag 20.04.25 15:00:32 von
neuester Beitrag 20.04.25 15:00:32 von
Beiträge: 26
ID: 230.027
ID: 230.027
Aufrufe heute: 0
Gesamt: 3.866
Gesamt: 3.866
Aktive User: 0
ISIN: US74834L1008 · WKN: 904533 · Symbol: DGX
178,12
USD
+0,08 %
+0,15 USD
Letzter Kurs 22:15:00 NYSE
NYSE
Neuigkeiten
| Titel |
|---|
16.05.25 Stochastik Signal long |
12.05.25 Verkauf |
22.04.25 · wO Chartvergleich |
21.04.25 · BörsenNEWS.de |
07.04.25 · Markt Bote |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,0000 | +93,55 | |
| 6,1500 | +75,21 | |
| 0,5950 | +34,01 | |
| 0,9500 | +25,00 | |
| 26,40 | +24,24 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8756 | -14,16 | |
| 16,900 | -14,99 | |
| 103,50 | -14,81 | |
| 2,4000 | -19,73 | |
| 0,6136 | -14,07 |
Beitrag zu dieser Diskussion schreiben
Durchsuchen
- 1
- ►
- …
- 3
Begriffe und/oder Benutzer
Top-Postings
Ja Nein
Bevorstehender Unternehmenstermin
Bei Quest Diagnostics steht morgen der Termin "Quartalsmitteilung" vor Öffnung an.21 Nutzer haben Quest Diagnostics im Portfolio und 51 unserer Nutzer haben Quest Diagnostics auf der Watchlist.
Weitere Nachrichten zu Quest Diagnostics finden Sie auf der Quest Diagnostics Wertpapierdetailseite im Bereich "Neuigkeiten" und unter "Übersicht".
Eine Übersicht aller Unternehmenstermine finden Sie hier.
Quest Diagnostics Earnings Per Share Increase 70% in Third Quarter 2001
TETERBORO, N.J., Oct. 18 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX - news), the nation`s leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2001, net income was $50.1 million, or $0.51 per diluted share, up 70% from the $28.7 million, or $0.30 per diluted share, reported in 2000. The company estimates that earnings were reduced by $0.03 per diluted share as a result of the tragic events of September 11. Cash earnings, or earnings before amortization of intangible assets, rose to $0.61 per diluted share from $0.41 per diluted share for the 2000 period.
Third quarter revenues of $903 million grew by $53 million, or more than 6%, over last year, primarily driven by improved revenue per requisition. The revenue impact of the September 11 tragedy was approximately $8 million, or 1%. Clinical testing volume, measured by the number of requisitions, increased approximately 2% over the prior year period, excluding the impact of the tragedy and adjusting for business contributed to unconsolidated joint ventures. As a result, reported volume during the third quarter equaled the prior year`s level.
``The strong results reflect continued improvement in operating performance and actions taken to strengthen our balance sheet,`` said Kenneth W. Freeman, Chairman and Chief Executive Officer. ``Our business, like many others in the New York metropolitan area, was impacted by the tragic events of September 11. The focused efforts of our employees, coupled with our logistics capability, geographic breadth and scale enabled us to mitigate what could have otherwise been a much more severe impact to our business and our customers. We now expect full-year 2001 earnings per share before special items to grow more than 65% from last year and are comfortable with the current consensus of earnings per share estimates of $0.48 for the fourth quarter, as published by First Call. In addition, we continue to expect to deliver earnings growth in excess of 30% in 2002.``
o--h.W^"ngs before interest, taxes, depreciation, amortization and special
items (adjusted EBITDA), were $142 million, or 15.7% of revenues, compared to
$120 million, or 14.1%, for the prior year period. The increase in adjusted
EBITDA was due to the company`s revenue growth and improved operating
performance.
Days sales outstanding were 53 days, compared to 54 days a year ago. Bad debt was 6.1% of revenues in the quarter, compared to 6.8% in the prior year period. The company ended the quarter with nearly $240 million in cash and no borrowings outstanding under its $325 million revolving credit facility. Capital expenditures totaled $32 million for the quarter.
For the first nine months of 2001, income before special items increased to $136.6 million, or $1.40 per diluted share, compared to $78.0 million, or $0.83 per diluted share, in 2000. Revenues increased by $133 million to $2.7 billion. Adjusted EBITDA was $413 million, or 15.2% of revenues for the nine-month period, compared to $347 million, or 13.4% a year ago. Capital expenditures for the nine-month period totaled $110 million.
TETERBORO, N.J., Oct. 18 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX - news), the nation`s leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2001, net income was $50.1 million, or $0.51 per diluted share, up 70% from the $28.7 million, or $0.30 per diluted share, reported in 2000. The company estimates that earnings were reduced by $0.03 per diluted share as a result of the tragic events of September 11. Cash earnings, or earnings before amortization of intangible assets, rose to $0.61 per diluted share from $0.41 per diluted share for the 2000 period.
Third quarter revenues of $903 million grew by $53 million, or more than 6%, over last year, primarily driven by improved revenue per requisition. The revenue impact of the September 11 tragedy was approximately $8 million, or 1%. Clinical testing volume, measured by the number of requisitions, increased approximately 2% over the prior year period, excluding the impact of the tragedy and adjusting for business contributed to unconsolidated joint ventures. As a result, reported volume during the third quarter equaled the prior year`s level.
``The strong results reflect continued improvement in operating performance and actions taken to strengthen our balance sheet,`` said Kenneth W. Freeman, Chairman and Chief Executive Officer. ``Our business, like many others in the New York metropolitan area, was impacted by the tragic events of September 11. The focused efforts of our employees, coupled with our logistics capability, geographic breadth and scale enabled us to mitigate what could have otherwise been a much more severe impact to our business and our customers. We now expect full-year 2001 earnings per share before special items to grow more than 65% from last year and are comfortable with the current consensus of earnings per share estimates of $0.48 for the fourth quarter, as published by First Call. In addition, we continue to expect to deliver earnings growth in excess of 30% in 2002.``
o--h.W^"ngs before interest, taxes, depreciation, amortization and special
items (adjusted EBITDA), were $142 million, or 15.7% of revenues, compared to
$120 million, or 14.1%, for the prior year period. The increase in adjusted
EBITDA was due to the company`s revenue growth and improved operating
performance.
Days sales outstanding were 53 days, compared to 54 days a year ago. Bad debt was 6.1% of revenues in the quarter, compared to 6.8% in the prior year period. The company ended the quarter with nearly $240 million in cash and no borrowings outstanding under its $325 million revolving credit facility. Capital expenditures totaled $32 million for the quarter.
For the first nine months of 2001, income before special items increased to $136.6 million, or $1.40 per diluted share, compared to $78.0 million, or $0.83 per diluted share, in 2000. Revenues increased by $133 million to $2.7 billion. Adjusted EBITDA was $413 million, or 15.2% of revenues for the nine-month period, compared to $347 million, or 13.4% a year ago. Capital expenditures for the nine-month period totaled $110 million.
Das Biest kommt wieder....
hey, joe
hey, joe
die aktie ist teuer, das wachstum wird wahrscheinlich nachlassen:
Last Year`s Best Bet? A Company Called Quest
Fortune
The medical lab-testing provider and its stock grew tremendously last year, and if it stays on track it looks like a long-term good investment. "The future of medicine is stuffed to the ills with new tests," which bodes well for the firm. It is "the nation`s leading testing company, with 1300 patient centers, 30 major labs, and 150 labs that deliver results, stat. The company `turns` 400000 specimens a day, its earnings are jumping more than 25% annually, and it has 10% of the $35 billion testing market." Andrea Bici, analyst at CSFB, feels the outfit`s efficient billing process is good for business.Do not look to the company for the same astounding growth this year as last year. This year the firm "settled a $13.1 million suit that alleged it had defrauded federal health programs through inflated billings. And then there`s the fact that Wall Street finally caught on" to the outfit`s story. The security, which is "trading for 34 times Bici`s estimate of earnings for this year, is an expensive stock."
gruss
schurke
Last Year`s Best Bet? A Company Called Quest
Fortune
The medical lab-testing provider and its stock grew tremendously last year, and if it stays on track it looks like a long-term good investment. "The future of medicine is stuffed to the ills with new tests," which bodes well for the firm. It is "the nation`s leading testing company, with 1300 patient centers, 30 major labs, and 150 labs that deliver results, stat. The company `turns` 400000 specimens a day, its earnings are jumping more than 25% annually, and it has 10% of the $35 billion testing market." Andrea Bici, analyst at CSFB, feels the outfit`s efficient billing process is good for business.Do not look to the company for the same astounding growth this year as last year. This year the firm "settled a $13.1 million suit that alleged it had defrauded federal health programs through inflated billings. And then there`s the fact that Wall Street finally caught on" to the outfit`s story. The security, which is "trading for 34 times Bici`s estimate of earnings for this year, is an expensive stock."
gruss
schurke
hi leute,
hier eine meldung, die den teilweisen ausstieg von glaxosmithkline erklärt, was den kurs in den letzten tagen entgegen den trend belastete:
____________________________________________________________
GlaxoSmithKline Lowers Quest Diagnostics Stake To 23.7%
WASHINGTON -(Dow Jones)- GlaxoSmithKline Plc (GSK) decreased its stake in Quest Diagnostics Inc. (DGX) to 23.7%.
In a filing Monday with the Securities and Exchange Commission, GlaxoSmithKline said it beneficially holds 11.07 million common shares, after selling 1.5 million shares on May 2 for $119.50 a share.
On Aug. 25, GlaxoSmithKline reported a 29.2% stake in the company.
Quest Diagnostics, Teterboro, N.J., owns and operates clinical laboratories that perform tests on human tissue and fluids to diagnose, treat and monitor diseases.
-By Phil McCarty, Dow Jones Newswires; 202-862-9251
____________________________________________________________
gruss
schurke
hier eine meldung, die den teilweisen ausstieg von glaxosmithkline erklärt, was den kurs in den letzten tagen entgegen den trend belastete:
____________________________________________________________
GlaxoSmithKline Lowers Quest Diagnostics Stake To 23.7%
WASHINGTON -(Dow Jones)- GlaxoSmithKline Plc (GSK) decreased its stake in Quest Diagnostics Inc. (DGX) to 23.7%.
In a filing Monday with the Securities and Exchange Commission, GlaxoSmithKline said it beneficially holds 11.07 million common shares, after selling 1.5 million shares on May 2 for $119.50 a share.
On Aug. 25, GlaxoSmithKline reported a 29.2% stake in the company.
Quest Diagnostics, Teterboro, N.J., owns and operates clinical laboratories that perform tests on human tissue and fluids to diagnose, treat and monitor diseases.
-By Phil McCarty, Dow Jones Newswires; 202-862-9251
____________________________________________________________
gruss
schurke
Quest Diagnostics, Inc. (NYSE
GX) announced February 22 that its board of directors approved a 2:1 stock split to be effected on May 31, 2001.
Stock Split Details: http://biz.yahoo.com/n/d/dgx.html
Company Profile: http://biz.yahoo.com/p/d/dgx.html
Mini
GX) announced February 22 that its board of directors approved a 2:1 stock split to be effected on May 31, 2001.Stock Split Details: http://biz.yahoo.com/n/d/dgx.html
Company Profile: http://biz.yahoo.com/p/d/dgx.html
Mini
Hallo,
Quest will mit den earnings in line bleiben, 0.57-0.59 cent/s.
Die recom. sehen gut aus, wobei Piper Jefry heute von Strong buy auf buy herabgestuft hat, weil Quest ´nur´noch mit 6-8% Umsatz wachsen will/wird.
Der Gewinn hingegen soll auf 3,1-3,2 $/S (!)steigen.
Quest Diagnostics Revises Upward 2001 Guidance
PR Newswire - Tuesday, January 16, 2001
TETERBORO, N.J., Jan 16, 2001 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation`s leading provider of diagnostic testing, information and services, today announced that it has revised upward its estimate of diluted earnings per share, before special items, for the year ending December 31, 2001 to between $3.10 and $3.20, approximately 40% above the current consensus of analysts` estimates for the full-year 2000 and also above the current consensus estimate for 2001 of $2.97 per diluted share, as compiled by First Call. Cash earnings for 2001 are now estimated at between $3.90 and $4.00 per diluted share. This anticipated improvement reflects the continued positive impact of the 1999 acquisition of SmithKline Beecham Clinical Laboratories (SBCL), as well as favorable industry trends.
For the fourth quarter of 2000, the company expects to report earnings per diluted share before special items within the range of current analyst estimates of $0.57 to $0.59 per diluted share, despite recent severe weather in a number of important markets. In addition, the company prepaid $155 million of bank debt during the fourth quarter. As a result, the company will record an extraordinary loss of $0.06 per share associated with the write-off of deferred financing costs, a non-cash charge.
Fourth-quarter 2000 volume, measured by the number of requisitions, grew approximately 1% above the prior year, after adjusting for the impact of severe weather and the contribution of business to unconsolidated joint ventures. The company estimates that volume in the quarter was reduced by approximately 1.5% due to severe weather in several parts of the country in December. Additionally, reported volume was reduced by approximately 1.5% as a result of the contribution of certain SBCL business to unconsolidated joint ventures, as required by existing joint venture agreements. As a result of these items, reported volume during the fourth quarter will be approximately 2% below the prior year`s level. Revenue per requisition during the fourth quarter is expected to grow by almost 9% compared to the prior year. The company continues to benefit from its longstanding strategy of shedding unprofitable business and focusing on higher-value testing services.
"We had a terrific year in 2000. We nearly doubled earnings per share while integrating the largest acquisition in the history of our industry," said Kenneth W. Freeman, Chairman and Chief Executive Officer. "Looking forward to 2001, we anticipate earnings growth of approximately 40%. We expect to realize additional gains from the integration of Quest Diagnostics and SBCL, and to see improving volume comparisons after the completion of integration, scheduled for the end of the first quarter. We are the leader in an industry with improving fundamentals, and we are committed to continue to deliver outstanding results for our shareholders."
The company expects revenues for 2001 to grow between 6% and 8%, with volume and revenue per requisition each contributing approximately half of the increase. It expects EBITDA margins to approach 15%, interest expense of approximately $100 million to $105 million and amortization expense of approximately $45 million. Capital spending is expected to total between $130 million and $150 million.
Quest Diagnostics will release financial results for the fourth quarter and full year 2000 after the close of the stock market on January 29, 2001. The company is currently in a "quiet" period and will discuss results for the fourth quarter and full year 2000 during a conference call on January 30 at 8:00 A.M. (Eastern Time). To hear a simulcast of the call over the Internet, or a replay, registered analysts may access StreetEvents at: http://www.streetevents.com and all others may access the Quest Diagnostics website at: http://www.questdiagnostics.com. In addition, a replay of the call will also be available from 10 A.M. on January 30 through 5 P.M. on February 2 by dialing 800-695-4249.
Quest Diagnostics is the nation`s leading provider of diagnostic testing, information and services with annualized revenues of more than $3 billion. The testing performed on human specimens helps doctors diagnose, treat and monitor disease; enables employers to detect workplace drug abuse; and supports pharmaceutical and biotechnology companies in clinical trials of new therapeutics worldwide. Quest Informatics analyzes laboratory and other medical data to help health care providers improve the care of patients. Additional company information can be found on the Internet at: http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are listed in the Quest Diagnostics Incorporated 1999 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics
CONTACT: Cathy Doherty, Investors, 201-393-5030, or Gary Samuels, Media, 201-393-5700, both of Quest DiagnosticsURL: http://www.questdiagnostics.comhttp://www.prnewswire.com(C) 2001 PR Newswire. All rights reserved.
Quest will mit den earnings in line bleiben, 0.57-0.59 cent/s.
Die recom. sehen gut aus, wobei Piper Jefry heute von Strong buy auf buy herabgestuft hat, weil Quest ´nur´noch mit 6-8% Umsatz wachsen will/wird.
Der Gewinn hingegen soll auf 3,1-3,2 $/S (!)steigen.
Quest Diagnostics Revises Upward 2001 Guidance
PR Newswire - Tuesday, January 16, 2001
TETERBORO, N.J., Jan 16, 2001 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation`s leading provider of diagnostic testing, information and services, today announced that it has revised upward its estimate of diluted earnings per share, before special items, for the year ending December 31, 2001 to between $3.10 and $3.20, approximately 40% above the current consensus of analysts` estimates for the full-year 2000 and also above the current consensus estimate for 2001 of $2.97 per diluted share, as compiled by First Call. Cash earnings for 2001 are now estimated at between $3.90 and $4.00 per diluted share. This anticipated improvement reflects the continued positive impact of the 1999 acquisition of SmithKline Beecham Clinical Laboratories (SBCL), as well as favorable industry trends.
For the fourth quarter of 2000, the company expects to report earnings per diluted share before special items within the range of current analyst estimates of $0.57 to $0.59 per diluted share, despite recent severe weather in a number of important markets. In addition, the company prepaid $155 million of bank debt during the fourth quarter. As a result, the company will record an extraordinary loss of $0.06 per share associated with the write-off of deferred financing costs, a non-cash charge.
Fourth-quarter 2000 volume, measured by the number of requisitions, grew approximately 1% above the prior year, after adjusting for the impact of severe weather and the contribution of business to unconsolidated joint ventures. The company estimates that volume in the quarter was reduced by approximately 1.5% due to severe weather in several parts of the country in December. Additionally, reported volume was reduced by approximately 1.5% as a result of the contribution of certain SBCL business to unconsolidated joint ventures, as required by existing joint venture agreements. As a result of these items, reported volume during the fourth quarter will be approximately 2% below the prior year`s level. Revenue per requisition during the fourth quarter is expected to grow by almost 9% compared to the prior year. The company continues to benefit from its longstanding strategy of shedding unprofitable business and focusing on higher-value testing services.
"We had a terrific year in 2000. We nearly doubled earnings per share while integrating the largest acquisition in the history of our industry," said Kenneth W. Freeman, Chairman and Chief Executive Officer. "Looking forward to 2001, we anticipate earnings growth of approximately 40%. We expect to realize additional gains from the integration of Quest Diagnostics and SBCL, and to see improving volume comparisons after the completion of integration, scheduled for the end of the first quarter. We are the leader in an industry with improving fundamentals, and we are committed to continue to deliver outstanding results for our shareholders."
The company expects revenues for 2001 to grow between 6% and 8%, with volume and revenue per requisition each contributing approximately half of the increase. It expects EBITDA margins to approach 15%, interest expense of approximately $100 million to $105 million and amortization expense of approximately $45 million. Capital spending is expected to total between $130 million and $150 million.
Quest Diagnostics will release financial results for the fourth quarter and full year 2000 after the close of the stock market on January 29, 2001. The company is currently in a "quiet" period and will discuss results for the fourth quarter and full year 2000 during a conference call on January 30 at 8:00 A.M. (Eastern Time). To hear a simulcast of the call over the Internet, or a replay, registered analysts may access StreetEvents at: http://www.streetevents.com and all others may access the Quest Diagnostics website at: http://www.questdiagnostics.com. In addition, a replay of the call will also be available from 10 A.M. on January 30 through 5 P.M. on February 2 by dialing 800-695-4249.
Quest Diagnostics is the nation`s leading provider of diagnostic testing, information and services with annualized revenues of more than $3 billion. The testing performed on human specimens helps doctors diagnose, treat and monitor disease; enables employers to detect workplace drug abuse; and supports pharmaceutical and biotechnology companies in clinical trials of new therapeutics worldwide. Quest Informatics analyzes laboratory and other medical data to help health care providers improve the care of patients. Additional company information can be found on the Internet at: http://www.questdiagnostics.com.
The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are listed in the Quest Diagnostics Incorporated 1999 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics
CONTACT: Cathy Doherty, Investors, 201-393-5030, or Gary Samuels, Media, 201-393-5700, both of Quest DiagnosticsURL: http://www.questdiagnostics.comhttp://www.prnewswire.com(C) 2001 PR Newswire. All rights reserved.
Hallo Stockmanager,
viel ist ja nicht passiert nach der Meldung...
Bist Du noch dabei? Der superagent ist ja ausgestiegen und ich bin mir auch nicht mehr so sicher. Ich verstehe einfach zu wenig von der Materie...
Ciao, PiratPilot
viel ist ja nicht passiert nach der Meldung...
Bist Du noch dabei? Der superagent ist ja ausgestiegen und ich bin mir auch nicht mehr so sicher. Ich verstehe einfach zu wenig von der Materie...
Ciao, PiratPilot
Mein absoluter Tipp für schnellentschlossene:
http://biz.yahoo.com/prnews/001212/nj_quest_d.html
Quest Diagnostic hat gestern nach Börsenschluss gemeldet, dass man einen bahnbrechenenden Erfolg in Sachen AIDS-Bekämpfung gemacht hat.
Wenn heute mittag die US-Börse aufmacht, dann wird der Kurs wohl hochschiessen.
Hier in Deutschland scheint keiner so richtig aufzupassen, denn die AKtie ist noch zum Schlusskurs von gestern zu kriegen.
WKN: 904 533, Last trade 142 in Frankfurt.
Ich wünsche allen gutes Trading
http://biz.yahoo.com/prnews/001212/nj_quest_d.html
Quest Diagnostic hat gestern nach Börsenschluss gemeldet, dass man einen bahnbrechenenden Erfolg in Sachen AIDS-Bekämpfung gemacht hat.
Wenn heute mittag die US-Börse aufmacht, dann wird der Kurs wohl hochschiessen.
Hier in Deutschland scheint keiner so richtig aufzupassen, denn die AKtie ist noch zum Schlusskurs von gestern zu kriegen.
WKN: 904 533, Last trade 142 in Frankfurt.
Ich wünsche allen gutes Trading
Durchsuchen22.04.25 · wO Chartvergleich · Capital One Financial |
21.04.25 · BörsenNEWS.de · Adobe |
07.04.25 · Markt Bote · American Eagle Outfitters |
19.03.25 · wO Chartvergleich · Boeing |
19.03.25 · wO Newsflash · American Express |
19.03.25 · wO Newsflash · American Express |
19.03.25 · wO Newsflash · American Express |
